Found: 35
Select item for more details and to access through your institution.
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.
- Published in:
- BioDrugs, 2024, v. 38, n. 6, p. 755, doi. 10.1007/s40259-024-00671-4
- By:
- Publication type:
- Article
Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2022, v. 8, n. 3, p. 1, doi. 10.1177/20552173221115023
- By:
- Publication type:
- Article
The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod.
- Published in:
- Multiple Sclerosis Journal - Experimental, Translational & Clinical, 2019, v. 5, n. 1, p. 1, doi. 10.1177/2055217318819245
- By:
- Publication type:
- Article
Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
- Published in:
- Multiple Sclerosis (13524585), 2003, v. 9, n. 1, p. 59, doi. 10.1191/1352458503ms896oa
- By:
- Publication type:
- Article
A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping.
- Published in:
- Patient Preference & Adherence, 2021, v. 15, p. 975, doi. 10.2147/PPA.S297052
- By:
- Publication type:
- Article
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, p. 1, doi. 10.1177/17562864231194823
- By:
- Publication type:
- Article
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, v. 16, p. 1, doi. 10.1177/17562864231194823
- By:
- Publication type:
- Article
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 8, p. 1219, doi. 10.1177/13524585211049392
- By:
- Publication type:
- Article
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 14, p. 1866, doi. 10.1177/1352458519888610
- By:
- Publication type:
- Article
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 13, p. 1719, doi. 10.1177/1352458519881759
- By:
- Publication type:
- Article
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonâ-1a versus subcutaneous interferonβ- 1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
- Published in:
- BMC Neurology, 2012, v. 12, n. 1, p. 154, doi. 10.1186/1471-2377-12-154
- By:
- Publication type:
- Article
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
- Published in:
- BMC Neurology, 2010, v. 10, p. 28, doi. 10.1186/1471-2377-10-28
- By:
- Publication type:
- Article
Psychological Studies of Punishment.
- Published in:
- California Law Review, 1970, v. 58, n. 2, p. 405, doi. 10.2307/3479665
- By:
- Publication type:
- Article
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2021, v. 78, n. 1, p. 48, doi. 10.1001/jamaneurol.2020.2950
- By:
- Publication type:
- Article
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
- Published in:
- Journal of Neurology, 2024, v. 271, n. 6, p. 3116, doi. 10.1007/s00415-024-12305-4
- By:
- Publication type:
- Article
Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
- Published in:
- Journal of Neurology, 2020, v. 267, n. 1, p. 64, doi. 10.1007/s00415-019-09532-5
- By:
- Publication type:
- Article
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. 4, p. 158, doi. 10.7224/1537-2073.2018-087
- By:
- Publication type:
- Article
(DXT78) The FLUENT Study: Changes in Immune Cell Profile, and in Clinical and Safety Outcomes, in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 44
- By:
- Publication type:
- Article
(DXT77) Alemtuzumab Maintains Efficacy on Clinical and Magnetic Resonance Imaging Lesion Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in Relapsing-Remitting Multiple Sclerosis Patients: CARE-MS II Follow-up (TOPAZ Study).
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 43
- By:
- Publication type:
- Article
(DXT08) Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Diagnosed Within 3 or 4 Years Prior to the CLARITY Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 18
- By:
- Publication type:
- Article
(DMT02) Yearly Efficacy and Safety Outcomes Over 4 Years After Last Alemtuzumab Course in Pooled CAREMS I and II Patients by Number of Additional Courses Received Through Year 9.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 4
- By:
- Publication type:
- Article
Occult Belief: Seeing Is Believing.
- Published in:
- Journal for the Scientific Study of Religion, 1980, v. 19, n. 4, p. 337, doi. 10.2307/1386128
- By:
- Publication type:
- Article
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286421993999
- By:
- Publication type:
- Article
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2021, p. 1, doi. 10.1177/1756286421993999
- By:
- Publication type:
- Article
The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 9, p. 327, doi. 10.1177/1756285617716002
- By:
- Publication type:
- Article
Initiating oral fingolimod treatment in patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2013, v. 6, n. 4, p. 269, doi. 10.1177/1756285613491520
- By:
- Publication type:
- Article
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 4, p. 1273, doi. 10.1007/s40120-024-00637-2
- By:
- Publication type:
- Article
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 2, p. 283, doi. 10.1007/s40120-023-00565-7
- By:
- Publication type:
- Article
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.
- Published in:
- Neurology & Therapy, 2020, v. 9, n. 2, p. 443, doi. 10.1007/s40120-020-00191-7
- By:
- Publication type:
- Article
Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors.
- Published in:
- Neurology & Therapy, 2016, v. 5, n. 2, p. 155, doi. 10.1007/s40120-016-0047-3
- By:
- Publication type:
- Article
Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 14, p. 1795, doi. 10.1177/13524585231205708
- By:
- Publication type:
- Article
Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 7, p. 3199, doi. 10.1007/s12325-022-02164-8
- By:
- Publication type:
- Article
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 4, p. 1810, doi. 10.1007/s12325-022-02068-7
- By:
- Publication type:
- Article